While IFN-γ is an attractive therapeutic candidate to restore MOB, data presented in the current study suggest that the efficacy that this drug has shown in the treatment of CGD,7 and tuberculosis,19, 20 is unlikely to extend to patients with SAH. The gene discussed is IFNG; the disease is chronic granulomatous disease.